Breaking News

Ginkgo, SaponiQx Awarded $31M to Develop Next-Gen Vaccine Adjuvants

Aim to use a combination of high-throughput empirical and AI/machine learning approaches to develop novel saponin-based adjuvants.

Author Image

By: Charlie Sternberg

Associate Editor

The Defense Threat Reduction Agency’s (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program has awarded a 5-year contract totaling up to $31 million including program options to the team of Ginkgo Bioworks Inc. and SaponiQx, Inc. (a subsidiary of Agenus Inc.) to discover and develop next-generation vaccine adjuvants.   Partners in adjuvant discovery and development since 2021, Ginkgo, which is building a platform for cell programming and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters